Clinical trials
for patients
Learn about available clinical trials
-
September 3, 2025Pamplona/MadridIn recruitmentEarly phase
ZN-c3-005 Phase II clinical trial to evaluate the efficacy and safety of ZN-c3 in patients with high-grade serous ovarian, fallopian tube or primary peritoneal ovarian cancer
The main objective of this study is: Part 1b: To determine the safety and tolerability of ZN-c3 in PROC subjects Part 2: To investigate the antitumor activity of ZN-c3 in PROC subjects -
September 1, 2025PamplonaIn recruitment
AC220-168 Phase III, double-blind, randomized, placebo-controlled clinical trial of quizartinib administered in combination with induction and consolidation chemotherapy and as maintenance therapy in adult patients with a diagnosis of
The purpose of this trial is to learn more about an investigational drug called QUIZARTINIB. An investigational drug is a drug that is not approved to treat your disease. It is being studied to see if your disease or medical condition improves while you are receiving it and if it is safe for people who have the same disease as you. -
August 27, 2025Pamplona/MadridIn recruitment
-
August 25, 2025PamplonaIn recruitment
PLATFORMPACAN1001 Ensayo clínico para la continuación del tratamiento del estudio y el seguimiento de la seguridad.
Clinical trial for continuation of study treatment and safety monitoring. -
August 18, 2025Pamplona/MadridIn recruitment
J2N-MC-JZNZ Clinical trial to determine the dose of Pirtobrutinib in adults with immune thrombocytopenia
The main objective is to ensure the safety and efficacy of Pirtobrutinib in patients with immune thrombocytopenia, and to select the doses for part 2 of this study. -
August 7, 2025Pamplona/MadridIn recruitmentEarly phase
ASTX030-01 Study of ASTX030 (cedazuridine in combination with azacitidine) in MDS, CMML or AML
The purpose of this study is to analyze the levels of the experimental drug ASTX030 in their blood, to assess the safety and tolerability of the drugs, and to find out how the participants respond to the drug. -
August 5, 2025Pamplona/MadridIn recruitmentEarly phase
CYTB323K12201 Trial of rapcabtagene autoleucel versus rituximab in participants with severe refractory diffuse diffuse cutaneous systemic sclerosis
The purpose of this study is to find out if YTB323 is safe and effective (if it can help) in people with severe refractory ESCD. -
August 5, 2025Pamplona/MadridIn recruitmentEarly phase
YL201-INT-101-01 Clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of YL201 as a single drug and in combination with other anticancer treatments in patients with advanced solid tumors
The main goal of this study is to examine YL201 in monotherapy (part 2 participants) or in combination with atezolizumab (part 3 participants) at different doses, to find out if the study treatment is safe, to understand how the body processes the study treatment, and to understand what the study treatment does to the body and its cancer. -
July 29, 2025Pamplona/MadridIn recruitment
75276617AML3001 Clinical trial of bleximenib, venetoclax and azacitidine for the treatment of newly diagnosed acute myeloid leukemia patients with KMT2A rearrangements or NPM1 mutations who are ineligible for intensive chemotherapy
The aim of this study is to help researchers better understand the potential efficacy and safety of BLEXIMENIB (also known as JNJ-75276617) in patients with newly diagnosed acute myeloid leukemia (ND-AML) with KMT2A or NPM1 DNA abnormalities when administered in addition to reference drugs, venetoclax and azacitidine. -
July 29, 2025Pamplona/MadridIn recruitment
D516KC00001 Clinical trial of Dato-DXd, with or without osimertinib, versus platinum derivative chemotherapy in participants with locally advanced or metastatic EGFR-mutated non-small cell lung cancer
The objective of this study is to evaluate whether Dato-DXd alone (monotherapy), or in combination with osimertinib, can safely allow longer disease control compared to the current gold standard treatment (GT) option of chemotherapy in patients who have failed prior osimertinib treatment.